

# Michel Delforge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2465006/publications.pdf>

Version: 2024-02-01

210  
papers

11,165  
citations

81434

41  
h-index

36203

101  
g-index

214  
all docs

214  
docs citations

214  
times ranked

12528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2023, 108, 890-897.	1.7	65
2	Combined lenalidomide/bortezomib for multiple myeloma complicated by fulminant myocarditis: a rare case report of widely used chemotherapy. <i>European Heart Journal - Case Reports</i> , 2022, 6, ytac093.	0.3	4
3	Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 243-250.	1.0	4
4	Upfront stem cell transplantation for newly diagnosed multiple myeloma with del(17p) and t(4;14): a study from the CMWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 210-217.	1.3	7
5	Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR. <i>Leukemia</i> , 2021, 35, 1732-1744.	3.3	5
6	Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 227-237.	0.8	22
7	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	3.3	79
8	Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder. <i>Acta Clinica Belgica</i> , 2021, 76, 49-52.	0.5	2
9	Ultra-low coverage whole genome sequencing of ccfDNA in multiple myeloma: A tool for laboratory routine?. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100380.	0.7	3
10	Identifying frailty in clinically fit patients diagnosed with hematological malignancies using a simple clinico-biological screening tool: The HEMA-4 study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 902-908.	0.5	7
11	Idecabtagene vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 705-716.	13.9	1,129
12	Immunomodulators in newly diagnosed multiple myeloma: current and future concepts. <i>Expert Review of Hematology</i> , 2021, 14, 365-376.	1.0	4
13	Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel,) Tj ETQq1 1 0.784314 rgBT /Overl multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2482-2491.	0.6	11
14	Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative Study. <i>Frontiers in Medicine</i> , 2021, 8, 686165.	1.2	21
15	Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1378-1390.	5.1	84
16	Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. <i>HemaSphere</i> , 2021, 5, e528.	1.2	45
17	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	2.2	46
18	OAB-023: Efficacy and safety of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with progressive multiple myeloma after 1-3 prior lines of therapy: Initial results from CARTITUDE-2. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S15.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting. <i>Blood</i> , 2021, 138, 3803-3803.	0.6	0
20	Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the KarMMA Clinical Trial. <i>Blood</i> , 2021, 138, 3041-3041.	0.6	1
21	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	0.6	1
22	Characteristics and Outcomes of Newly Diagnosed Multiple Myeloma Patients with and without Extramedullary Disease after Autologous Transplant and Maintenance Therapy: A Study from the CmwP-EBMT. <i>Blood</i> , 2021, 138, 485-485.	0.6	0
23	Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2. <i>Blood</i> , 2021, 138, 3866-3866.	0.6	17
24	A Phase I Study of RO7297089, a B-Cell Maturation Antigen (BCMA)-CD16a Bispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 2755-2755.	0.6	10
25	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). <i>Blood</i> , 2021, 138, 1835-1835.	0.6	10
26	Updated Health-Related Quality of Life Results from the KarMMA Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121). <i>Blood</i> , 2021, 138, 2835-2835.	0.6	5
27	CARTITUDE-2: Efficacy and Safety of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T-Cell Therapy, in Patients with Multiple Myeloma and Early Relapse after Initial Therapy. <i>Blood</i> , 2021, 138, 2910-2910.	0.6	11
28	Real-World Outcomes for Standard-of-Care Treatments in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 4075-4075.	0.6	3
29	A Multi-Center, Phase 1b Study to Assess the Safety, Pharmacokinetics and Efficacy of Subcutaneous Isatuximab Plus Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 2744-2744.	0.6	3
30	Daratumumab (DARA) with Bortezomib, Thalidomide, and Dexamethasone (VTd) in Transplant-Eligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) Negativity in Cassiopeia Part 1 and Part 2. <i>Blood</i> , 2021, 138, 82-82.	0.6	10
31	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1631-1631.	0.6	0
32	Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMA) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up. <i>Blood</i> , 2021, 138, 1978-1978.	0.6	0
33	P-162: Compass: a prospective study comparing clinical evaluation with different geriatric screening methods in newly diagnosed elderly multiple myeloma patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S124.	0.2	3
34	P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMA phase 2 trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S139-S140.	0.2	0
35	OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S17-S18.	0.2	7
36	Carfilzomib-induced reticulocytosis in patients with multiple myeloma is caused by impaired terminal erythroid maturation. <i>Leukemia</i> , 2020, 34, 651-655.	3.3	0

#	ARTICLE	IF	CITATIONS
37	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020, 10, e034209.	0.8	3
38	COVID-19, impact on myeloma patients. <i>Annals of Hematology</i> , 2020, 99, 1947-1949.	0.8	9
39	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.4	13
40	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
41	Ultra-low depth sequencing of plasma cell <scp>DNA</scp> for the detection of copy number aberrations in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 465-471.	1.5	3
42	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
43	Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial. <i>Blood</i> , 2020, 136, 28-29.	0.6	13
44	Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial. <i>Blood</i> , 2020, 136, 14-15.	0.6	5
45	KarMMA-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 24-25.	0.6	11
46	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
47	Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma. <i>British Journal of Haematology</i> , 2019, 187, 447-458.	1.2	7
48	Oral Selinexorâ€“Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
49	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	6.3	435
50	Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. <i>Health Science Reports</i> , 2019, 2, e104.	0.6	16
51	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	6.3	665
52	The treatment of multiple myeloma in an era of precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 153-162.	0.4	3
53	Velocities of Naturally Occurring Myocardial Shear Waves Increase With Age and in Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 2389-2398.	2.3	60
54	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33

#	ARTICLE	IF	CITATIONS
55	Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. <i>Haematologica</i> , 2019, 104, 2358-2360.	1.7	18
56	Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e3-e4.	0.2	18
57	Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e2-e3.	0.2	4
58	Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study. <i>Blood</i> , 2019, 134, 1850-1850.	0.6	6
59	Faster and sustained improvement in health-related quality of life (HRQoL) for newly diagnosed multiple myeloma (NDMM) patients ineligible for transplant treated with daratumumab, lenalidomide, and dexamethasone (D-Rd) versus Rd alone: MAIA. <i>Journal of Clinical Oncology</i> , 2019, 37, 8016-8016.	0.8	7
60	Characterization of Relapse and Second-Line Therapy in Lenalidomide-Refractory, Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: A Subanalysis of the Phase 3 First Trial. <i>Blood</i> , 2019, 134, 3122-3122.	0.6	0
61	The Locomotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression. <i>Blood</i> , 2019, 134, 5549-5549.	0.6	1
62	Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. <i>Leukemia</i> , 2018, 32, 1815-1818.	3.3	17
63	Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. <i>Nature Communications</i> , 2018, 9, 502.	5.8	84
64	Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?. <i>Annals of Hematology</i> , 2018, 97, 387-400.	0.8	21
65	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	1.2	41
66	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	3.3	68
67	Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone. <i>Leukemia and Lymphoma</i> , 2018, 59, 398-405.	0.6	13
68	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	0.6	216
69	Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. <i>Lancet Haematology</i> , 2018, 5, e479-e492.	2.2	25
70	European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. <i>Haematologica</i> , 2018, 103, 1772-1784.	1.7	86
71	Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S249-S250.	0.2	6
72	Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. <i>European Journal of Haematology</i> , 2018, 101, 556-565.	1.1	15

#	ARTICLE	IF	CITATIONS
73	Association between Patient Profile and Outcomes of Best Responders to Carfilzomib: A Post-Hoc Sub-Group Analysis of Aspire and Endeavor. <i>Blood</i> , 2018, 132, 3299-3299.	0.6	1
74	Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM. <i>Blood</i> , 2018, 132, 598-598.	0.6	17
75	Cognitive Impairment, Hypoalbuminemia, High CRP Level and Past History of Gastro-Intestinal Ulcer: 4 Markers of Frailty Which Identify Older Patients with Malignant Hemopathies Who Shouldn't Benefit from Chemotherapy. <i>Blood</i> , 2018, 132, 4756-4756.	0.6	0
76	Proteasome Inhibition By Carfilzomib Impairs Terminal Erythroid Maturation and Causes Reticulocytosis in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 1036-1036.	0.6	0
77	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1872-1879.	0.6	50
78	How I manage the toxicities of myeloma drugs. <i>Blood</i> , 2017, 129, 2359-2367.	0.6	44
79	Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasia. <i>Cytotherapy</i> , 2017, 19, 744-755.	0.3	3
80	Low frequency mutations in ribosomal proteins RPL10 and RPL5 in multiple myeloma. <i>Haematologica</i> , 2017, 102, e317-e320.	1.7	27
81	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis. <i>European Journal of Haematology</i> , 2017, 99, 199-206.	1.1	21
82	Echo Parameters for Differential Diagnosis in Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, e005588.	1.3	198
83	Multiple myeloma: new treatments gain momentum. <i>Lancet, The</i> , 2017, 389, 480-482.	6.3	2
84	Blinatumomab in relapsed/refractory diffuse large B cell lymphoma. <i>Annals of Hematology</i> , 2017, 96, 1759-1762.	0.8	2
85	Multiple myeloma: practice patterns across Europe. <i>British Journal of Haematology</i> , 2016, 175, 66-76.	1.2	91
86	Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. <i>Drugs</i> , 2016, 76, 853-867.	4.9	34
87	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	0.6	144
88	Concise review •Treatment of multiple myeloma in the very elderly: How do novel agents fit in?. <i>Journal of Geriatric Oncology</i> , 2016, 7, 383-389.	0.5	10
89	Multiple myeloma: patient outcomes in real-world practice. <i>British Journal of Haematology</i> , 2016, 175, 252-264.	1.2	220
90	Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. <i>Haematologica</i> , 2016, 101, 872-878.	1.7	19

#	ARTICLE	IF	CITATIONS
91	Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, e109-e112.	0.2	15
92	Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. <i>Leukemia and Lymphoma</i> , 2016, 57, 2833-2838.	0.6	27
93	The Relation of Ejection Fraction and Global Longitudinal Strain in Amyloidosis: Implications for Differential Diagnosis. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1358-1359.	2.3	38
94	Lymphoproliferative associated type 1 cryoglobulinemia. <i>Acta Clinica Belgica</i> , 2016, 71, 120-121.	0.5	0
95	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	0.6	30
96	Lack of clinical benefit of zoledronic acid in myelofibrosis: results of a prospective multi-center phase II trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 470-473.	0.6	3
97	A Phase 3 Randomized Placebo (PBO)-Controlled Double-Blind Trial of Darbepoetin Alfa in the Treatment of Anemia in Patients with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 2010-2010.	0.6	3
98	Final Analysis of Overall Survival from the First Trial. <i>Blood</i> , 2016, 128, 241-241.	0.6	11
99	Exploration of Survival Stratification of Patients with Multiple Myeloma after First Relapse Using Real World Data. <i>Blood</i> , 2016, 128, 2417-2417.	0.6	1
100	Adverse event (AE) management in patients (pts) with relapsed and refractory multiple myeloma (RRMM) taking pomalidomide (POM) plus low dose-dexamethasone (LoDEX): A pooled analysis from 3 clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8031-8031.	0.8	0
101	Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2016, 128, 2266-2266.	0.6	1
102	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. <i>Blood</i> , 2016, 128, 4414-4414.	0.6	0
103	The Value of Risk Stratification Tools in Multiple Myeloma (MM) in the Real-World: Validation of the Revised- International Staging System (R-ISS) at Initiation of Treatment and Relevance of the ISS and the R-ISS for Risk Stratification in the Relapsed Setting Using Data from the Czech Registry of Monoclonal Gammopathies (RMG). <i>Blood</i> , 2016, 128, 2418-2418.	0.6	1
104	Prediction of Poor Outcome in Older Patients Receiving Chemotherapy for Malignant Lymphoma: A New Frailty Scoring. <i>Blood</i> , 2016, 128, 2353-2353.	0.6	0
105	Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology. <i>Haematologica</i> , 2015, 100, 677-682.	1.7	18
106	Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. <i>Haematologica</i> , 2015, 100, 826-833.	1.7	76
107	Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. <i>Haematologica</i> , 2015, 100, 1327-1333.	1.7	68
108	Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. <i>Lancet Haematology</i> , 2015, 2, e55-e65.	2.2	115

#	ARTICLE	IF	CITATIONS
109	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. <i>Annals of Hematology</i> , 2015, 94, 23-34.	0.8	12
110	Optimizing quality of life in multiple myeloma patients: current options, challenges and recommendations. <i>Expert Review of Hematology</i> , 2015, 8, 355-366.	1.0	23
111	Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2015, 100, 1334-1339.	1.7	44
112	Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the <scp>MM</scp>â€œ003 trial for pomalidomide plus lowâ€œdose dexamethasone. <i>British Journal of Haematology</i> , 2015, 168, 820-823.	1.2	21
113	Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study. <i>Blood</i> , 2015, 126, 2086-2086.	0.6	4
114	Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment. <i>Blood</i> , 2015, 126, 3031-3031.	0.6	3
115	An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 4225-4225.	0.6	3
116	Analysis of Patient (Pt) Outcomes By Prior Treatment and Depth of Response in Stratus (MM-010), a Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2015, 126, 1834-1834.	0.6	0
117	RPL5 Is a Candidate Tumor Suppressor on 1p22.1 in Multiple Myeloma of Which the Expression Is Linked to Bortezomib Response. <i>Blood</i> , 2015, 126, 2969-2969.	0.6	0
118	Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged â‰¥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1489-1497.	0.6	37
119	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90
120	Response evaluation and monitoring of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 33-42.	1.0	8
121	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	13.9	697
122	Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 557-563.	0.4	60
123	Bone healing with bortezomib-based regimens in multiple myeloma: a retrospective imaging study. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 387-394.	0.7	2
124	Being a hematologist. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 249-251.	0.7	0
125	Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). <i>Blood</i> , 2014, 124, 4755-4755.	0.6	10
126	Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 80-80.	0.6	2



#	ARTICLE	IF	CITATIONS
127	Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.. Journal of Clinical Oncology, 2014, 32, 8516-8516.	0.8	2
128	The STRATUS trial (MM-010): A single-arm phase 3b study of pomalidomide plus low-dose dexamethasone (POM + LoDEX) in refractory or relapsed and refractory multiple myeloma.. Journal of Clinical Oncology, 2014, 32, TPS8625-TPS8625.	0.8	2
129	Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma. Blood, 2014, 124, 4770-4770.	0.6	1
130	Healthcare Resource Utilization Trends over Time with Continuous Lenalidomide Treatment (Tx) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM). Blood, 2014, 124, 1326-1326.	0.6	0
131	Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians. Annals of Medicine, 2013, 45, 413-422.	1.5	11
132	Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2013, 14, 1055-1066.	5.1	710
133	A novel role of BMP4 in adult hematopoietic stem and progenitor cell homing via Smad independent regulation of integrin- $\beta$ 4 expression. Blood, 2013, 121, 781-790.	0.6	37
134	Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. Haematologica, 2013, 98, 784-788.	1.7	57
135	Patients with myelodysplastic syndrome and two clones with different interstitial deletions of the long arm of chromosome 5. Leukemia and Lymphoma, 2013, 54, 2314-2317.	0.6	0
136	Multiple myeloma treatment in the elderly. International Journal of Hematologic Oncology, 2013, 2, 265-268.	0.7	0
137	Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus) Tj ETQq1 1 0.784314 rgBT /Over (Pts) Ineligible For Stem Cell Transplantation (SCT). Blood, 2013, 122, 2-2.	0.6	39
138	Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) Improves Health-Related Quality Of Life (HRQoL) Vs High-Dose Dexamethasone (HiDEX) In Relapsed Refractory Multiple Myeloma (RRMM) Patients Enrolled In MM-003 Phase 3 Randomized Trial. Blood, 2013, 122, 2939-2939.	0.6	2
139	MM-003 Phase 3 Study Of Pomalidomide In Combination With Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM): POM + Lodex Is Beneficial For Elderly Patients (> 65 Years of Age). Blood, 2013, 122, 3198-3198.	0.6	2
140	Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial. Blood, 2013, 122, 3332-3332.	0.6	2
141	Final Analysis, Cytogenetics, Long-Term Treatment, and Long-Term Survival In MM-003, A Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 408-408.	0.6	10
142	Patient Outcomes By Prior Therapies and Depth Of Response: Analysis Of MM-003, a Phase 3 Study Comparing Pomalidomide + Low-Dose Dexamethasone (POM + LoDEX) Vs High-Dose Dexamethasone (HiDEX) In Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2013, 122, 686-686.	0.6	2
143	MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2013, 31, 8510-8510.	0.8	2
144	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).. Journal of Clinical Oncology, 2013, 31, 8527-8527.	0.8	7

#	ARTICLE	IF	CITATIONS
145	Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.. Journal of Clinical Oncology, 2013, 31, 8583-8583.	0.8	1
146	Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.. Journal of Clinical Oncology, 2013, 31, 8528-8528.	0.8	0
147	Lenalidomide (LEN)-melphalan-prednisone induction followed by LEN maintenance (MPR-R) in newly diagnosed multiple myeloma (NDMM) elderly patients (Pts) with moderate renal impairment (RI): MM-015 trial post-hoc analysis.. Journal of Clinical Oncology, 2013, 31, 8544-8544.	0.8	0
148	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). Blood, 2013, 122, 3185-3185.	0.6	0
149	Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. Haematologica, 2012, 97, 529-533.	1.7	22
150	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia, 2012, 26, 149-157.	3.3	664
151	Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1759-1769.	13.9	692
152	Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. European Journal of Haematology, 2012, 89, 16-27.	1.1	65
153	Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study. Blood, 2012, 120, LBA-6-LBA-6.	0.6	14
154	Bortezomib for previously untreated multiple myeloma. Expert Opinion on Pharmacotherapy, 2011, 12, 2553-2564.	0.9	7
155	Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Research, 2011, 21, 290-304.	5.7	710
156	Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. European Journal of Haematology, 2011, 86, 372-384.	1.1	77
157	Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes. Annals of Hematology, 2011, 90, 655-666.	0.8	12
158	Differentiation Potential of Human Postnatal Mesenchymal Stem Cells, Mesoangioblasts, and Multipotent Adult Progenitor Cells Reflected in Their Transcriptome and Partially Influenced by the Culture Conditions. Stem Cells, 2011, 29, 871-882.	1.4	155
159	Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist, 2011, 16, 388-403.	1.9	26
160	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Improves Health-Related Quality of Life (HRQoL), with Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years Benefiting From Delays in Disease Progression. Blood, 2011, 118, 3157-3157.	0.6	3
161	Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years.. Blood, 2011, 118, 3988-3988.	0.6	2
162	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide (Len) Combined with Melphalan and Prednisone Followed by Continuous Lenalidomide Maintenance (MPR-R) in Patients (Pts) ≥ 65 Years (Yrs) with Newly Diagnosed Multiple Myeloma (NDMM): Updated Results for Pts Aged 65-75 Yrs Enrolled in MM-015. Blood, 2011, 118, 475-475.	0.6	12

#	ARTICLE	IF	CITATIONS
163	Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial. <i>Blood</i> , 2011, 118, 476-476.	0.6	16
164	Current insight into thrombotic thrombocytopenic purpura. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 3-10.	0.5	17
165	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. <i>Haematologica</i> , 2010, 95, 1754-1761.	1.7	73
166	A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. <i>Blood</i> , 2010, 115, 1113-1120.	0.6	271
167	Threatening clots in MGUS and myeloma. <i>Blood</i> , 2010, 115, 4975-4976.	0.6	4
168	Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2010, 89, 1338-1345.	1.3	101
169	The t(14;20)(q32;q12): a rare cytogenetic change in multiple myeloma associated with poor outcome. <i>British Journal of Haematology</i> , 2010, 149, 901-904.	1.2	9
170	Myeloablative Conditioning Predisposes Patients for <i>Toxoplasma gondii</i> Reactivation after Allogeneic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2010, 50, 1127-1134.	2.9	77
171	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. <i>Lancet Oncology</i> , The, 2010, 11, 1086-1095.	5.1	187
172	Influence of Renal Function on Outcome of VAD or Bortezomib, Doxorubicin, Dexamethasone (PAD) Induction Treatment Followed by High-Dose Melphalan (HDM): A Subgroup Analysis From the HOVON-65/GMMG-HD4 Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2010, 116, 2396-2396.	0.6	4
173	Efficacy of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients with Relapsed/Refractory Multiple Myeloma: An Interim Report from an International Electronic Observational Study. <i>Blood</i> , 2010, 116, 3027-3027.	0.6	4
174	HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 40-40.	0.6	44
175	A Phase 3 Study Evaluating the Efficacy and Safety of Lenalidomide Combined with Melphalan and Prednisone In Patients $\geq$ 65 Years with Newly Diagnosed Multiple Myeloma (NDMM): Continuous Use of Lenalidomide Vs Fixed-Duration Regimens. <i>Blood</i> , 2010, 116, 622-622.	0.6	30
176	Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients. <i>Blood</i> , 2010, 116, 1939-1939.	0.6	0
177	Monocytes from patients with myelodysplastic syndromes are more resistant to inhibition by thalidomide. <i>American Journal of Hematology</i> , 2009, 84, 769-770.	2.0	0
178	Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. <i>British Journal of Haematology</i> , 2009, 146, 627-636.	1.2	63
179	Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders. <i>Clinica Chimica Acta</i> , 2009, 410, 54-58.	0.5	16
180	Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.. <i>Blood</i> , 2009, 114, 3873-3873.	0.6	7

#	ARTICLE	IF	CITATIONS
181	A Phase III Study to Determine the Efficacy and Safety of Lenalidomide in Combination with Melphalan and Prednisone (MPR) in Elderly Patients with Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 613-613.	0.6	23
182	Characterization of Patients with Multiple Myeloma Achieving Complete Response to Bortezomib: An Interim Report From An International Electronic Observational Study.. Blood, 2009, 114, 4938-4938.	0.6	0
183	International Observational Study On Bortezomib (VELCADE) in Relapsed Multiple Myeloma: Preliminary Efficacy and Quality of Life (QoL) Results From the Belgian Population.. Blood, 2009, 114, 4523-4523.	0.6	0
184	Monoclonal gammopathy of undetermined significance: significant beyond hematology. Mayo Clinic Proceedings, 2009, 84, 842-5.	1.4	3
185	The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: A single centre study of 131 patients. Leukemia Research, 2008, 32, 1026-1035.	0.4	29
186	Diagnostic performance of serum free light chain measurement in patients suspected of a monoclonal Bâ€cell disorder. British Journal of Haematology, 2008, 143, 496-502.	1.2	12
187	Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma. Leukemia and Lymphoma, 2008, 49, 2365-2366.	0.6	4
188	Final Analysis of HOVON-50 Randomized Phase III Study on the Effect of Thalidomide Combined with Adriamycine, Dexamethasone (AD) and High Dose Melphalan (HDM) in Patients with Multiple Myeloma (MM). Blood, 2008, 112, 157-157.	0.6	8
189	Bortezomibâ€™Melphalanâ€™Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.. Blood, 2008, 112, 1727-1727.	0.6	5
190	Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.. Blood, 2008, 112, 1741-1741.	0.6	4
191	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalanâ€™Prednisone Versus Melphalanâ€™Prednisone. Blood, 2008, 112, 2778-2778.	0.6	13
192	Successful Harvesting of Peripheral Hematopoietic Stem Cells after Induction Treatment with Bortezomib, Adriamycin, Dexamethasone (PAD) in Patients with Newly Diagnosed Multiple Myeloma (MM). Blood, 2008, 112, 3470-3470.	0.6	7
193	Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma. Blood, 2008, 112, 867-867.	0.6	11
194	The T(14;20)(q32;q12) : A Rare Cytogenetic Change in Multiple Myeloma Associated with Poor Outcome. Blood, 2008, 112, 2718-2718.	0.6	0
195	Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leukemia Research, 2007, 31, 1373-1382.	0.4	33
196	Response to Bortezomib Therapy for Multiple Myeloma (MM) in Actual Clinical Practice: Preliminary Effectiveness Findings of an International Observational Study.. Blood, 2007, 110, 4837-4837.	0.6	0
197	Serial Serum Cytokine Measurement in a Patient with Systemic Scleromyxedema.. Blood, 2007, 110, 5100-5100.	0.6	0
198	A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma.. Blood, 2007, 110, 443-443.	0.6	2

#	ARTICLE	IF	CITATIONS
199	Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).. Blood, 2007, 110, 1456-1456.	0.6	1
200	Allogeneic SCT with Matched Related and Unrelated Donors for Patients (pts) with Refractory Anemia (RA): Improved Survival after Introduction of Reduced Intensity Conditioning (RIC) Regimens.. Blood, 2006, 108, 519-519.	0.6	1
201	The CD40-Receptor Is Upregulated on Monocytes from Patients with Low-Risk Myelodysplastic Syndromes and Its Inhibition by a Monoclonal Anti-CD40 Antibody Can Increase Colony Formation.. Blood, 2006, 108, 2640-2640.	0.6	0
202	PAD Is a Highly Effective Regimen for the Treatment of Patients with Relapsed Refractory Multiple Myeloma.. Blood, 2006, 108, 5095-5095.	0.6	0
203	Mobilization of hematopoietic progenitors in low-grade myelodysplastic syndromes. Haematologica, 2006, 91, 572-3.	1.7	1
204	The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood, 2004, 103, 2908-2913.	0.6	102
205	Pain during bone marrow aspiration: prevalence and prevention. Journal of Pain and Symptom Management, 2003, 26, 860-866.	0.6	101
206	Amifostine does not preferentially stimulate the growth of residual polyclonal progenitor cells in myelodysplastic syndromes. Leukemia Research, 2003, 27, 593-598.	0.4	1
207	Evidence for position effects as a variantETV6-mediated leukemogenic mechanism in myeloid leukemias with a t(4;12)(q11-q12;p13) or t(5;12)(q31;p13). Blood, 2002, 99, 1776-1784.	0.6	79
208	Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. British Journal of Haematology, 1998, 102, 486-494.	1.2	38
209	Pathophysiology of CML: Do defects in integrin function contribute to the premature circulation and massive expansion of the BCR/ABL positive clone?. Translational Research, 1997, 129, 584-591.	2.4	41
210	Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after singleâ€dose cyclophosphamide combined with rhGMâ€CSF or rhGâ€CSF. British Journal of Haematology, 1995, 90, 384-392.	1.2	31